Baron Capital, a prominent investment management firm, recently disclosed its second-quarter 2026 investor letter for the Baron Discovery Fund. During this period, the fund achieved a 19.08% return (Institutional Shares), though it trailed the Russell 2000 Growth Index's 25.71% gain. This underperformance was largely attributed to the market's focus on AI-driven stocks, which benefited from a momentum-based trading environment. The fund's strategy emphasizes a long-term, balanced portfolio over short-term trends, drawing parallels between the current AI market enthusiasm and the dot-com bubble of the late 1990s, while remaining committed to fundamental company analysis and long-term valuation principles.
A key contributor to the Baron Discovery Fund's positive performance in Q2 2026 was its strategic stake in CareDx, Inc. (NASDAQ:CDNA). Established in 1998, CareDx is a leader in precision medicine, offering diagnostic tools for transplant patients. As of August 11, 2026, CareDx's stock was valued at $47.23 per share, boasting a market capitalization of $2.4 billion. The company recorded an impressive year-to-date increase of 150.69%, with a one-month return of 58.76% and a 52-week gain of 289.37%, reflecting robust market confidence and operational success.
The Baron Discovery Fund's decision to increase its position in CareDx proved prescient, especially following a significant decline in share value in Q3 2025. This downturn occurred after the Centers for Medicare and Medicaid Services (CMS) MolDX Program issued a draft local coverage decision (LCD) that threatened to limit reimbursement for CareDx's diagnostic tests. The fund viewed the stock's low point of $11-$12 as a "worst-case scenario" pricing and capitalized on the opportunity. Subsequently, shares rebounded into the high-$20s as investors gained a clearer understanding of the ongoing dialogue between CMS and stakeholders, and the potential for a more favorable final LCD. Further bolstering this recovery, CareDx announced strong first-quarter 2026 results, with revenues surging by 39% year-over-year and testing volumes up by 17%. The company also executed strategic divestitures and acquisitions, including the purchase of Naveris, signaling its entry into the head and neck cancer testing market, further diversifying its growth avenues.
The proactive investment strategy by the Baron Discovery Fund in CareDx, Inc. exemplifies how a commitment to fundamental analysis and long-term vision can yield substantial returns, even in volatile markets. This success underscores the importance of resilient leadership and adaptability in navigating regulatory challenges and expanding market presence, ultimately contributing to better patient outcomes and investor confidence.
